Body Composition

A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

A growth hormone-releasing hormone analog that was previously FDA-approved for diagnosing GH deficiency in children.

An FDA-approved GHRH analog used to reduce visceral fat in HIV-associated lipodystrophy.

An orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release.

A modified fragment of human growth hormone studied specifically for fat metabolism without the growth-promoting effects of full GH.

A mitochondria-derived peptide that regulates metabolic homeostasis and has been called an 'exercise mimetic.'

A synthetic growth hormone secretagogue that stimulates natural GH release, studied for body composition, recovery, and anti-aging.

A synthetic growth hormone secretagogue known for potent GH release and significant appetite stimulation through ghrelin receptor activation.

A modified growth hormone releasing hormone analog with a shorter half-life than DAC-conjugated CJC-1295, allowing more physiological GH pulsing.

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

A GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and weight management (Saxenda), the predecessor to semaglutide.

An investigational triple agonist (GIP/GLP-1/glucagon) that produced 24% weight loss in Phase II trials, potentially the most effective obesity drug.

The first GLP-1 receptor agonist, originally derived from Gila monster venom, FDA-approved for type 2 diabetes.

An FDA-approved synthetic analogue of amylin used alongside insulin for diabetes, also studied for weight management.

An FDA-approved MC4R agonist for rare genetic obesity disorders, representing a precision medicine approach to weight management.

A naturally occurring peptide hormone that raises blood sugar, FDA-approved as emergency treatment for severe hypoglycemia.

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.